NAMSA, a leading US based MedTech testing, clinical and regulatory consulting firm, announced that it finalized its acquisition of WuXi AppTec’s US medical device testing operations on February 28. The acquisition brings together two of the most trusted names in medical device biological safety testing, serving more than 4,000 manufacturers worldwide. NAMSA has been expanding its reach in recent years as it continues to diversify its offering beyond biological safety testing. Since 2021, the company has acquired no fewer than six companies focused on preclinical or clinical research, making NAMSA one of the leading MedTech focused CROs.
Read the full article: NAMSA Completes Acquisition of WuXi AppTec US Medical Device Testing Business //
Source: https://www.prnewswire.com/news-releases/namsa-completes-acquisition-of-wuxi-apptec-us-medical-device-testing-business-302389468.html